Dynavax (DVAX) Received its Third Buy in a Row


After Cowen & Co. and William Blair gave Dynavax (NASDAQ: DVAX) a Buy rating last month, the company received another Buy, this time from H.C. Wainwright. Analyst Edward White reiterated a Buy rating on Dynavax today and set a price target of $16.00. The company’s shares closed last Thursday at $8.16.

According to TipRanks.com, White is a top 100 analyst with an average return of 54.9% and a 59.1% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Karyopharm Therapeutics, and Silverback Therapeutics.

Currently, the analyst consensus on Dynavax is a Strong Buy with an average price target of $16.67.

See today’s analyst top recommended stocks >>

Based on Dynavax’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $13.41 million and net profit of $4.4 million. In comparison, last year the company earned revenue of $10.58 million and had a GAAP net loss of $33.46 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the development and discovery of novel vaccines and immuno-oncology therapeutics. It focuses on leveraging the body’s innate and adaptive immune responses through toll-like receptor stimulation. It offers products for vaccines, cancer immunotherapy, and immune-mediated diseases. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Berkeley, CA.

Read More on DVAX:

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts